anoth reset takeaway
miss core growth vs trim rev/ep guidanc
order delay among us pharma custom concern
persist weak instrument demand ytd continu weigh
recur rev ballast growth time prospect
easi comp new product cycl hold promis better stock alreadi
seem discount growth recoveri view
growth deceler continu core growth miss expect
third straight attribut unanticip soft us pharma late
end-market pharma slow short-liv pick-up despit
easier comp industri flat gov t/academ less
line region america fell vs eu flat asia grew vs
china led dd growth pharma headwind abat
somewhat order activ gener custom continu rebound overal
revenu shortfal seem concentr pharma channel overshadow
pocket strength elsewher ytd good stabil
ii ta instrument return growth weak start iii recur rev
mix grew albeit somewhat slower clip bottom
line ep match consensu better profit off-set weaker rev
guidanc cut outlook factor us pharma rebound cut core growth
outlook third time row far cri
average tool peer impli slowest yr sinc also
cut ep mid-pt assum core growth
line ytd trend impli modest acceler stack comp princip
driven q/q catch-up delay pharma order us contribut
sever new product cyclic im synapt xs xevo tq- normal yr-end budget
flush along one extra sell day
thought set-up prospect seem hing stabil
industri ytd small molecul pharma rev meaning new
product contribut despit easi comp soon make case
normal yr rel core ltg model view revis ep
 higher net interest share repurchas
assum use rest author exit target
maintain neutral stanc stock ytd even ep trend
lower start year latest reset despit continu below-p
growth trade ebitda line w/ peer think alreadi
discount growth recoveri next year pend greater confid around potenti
newer product intro stem share loss restor growth remain
pleas see analyst certif import disclosur inform inform regard statu non-u analyst
page report
pleas see import disclosur inform page report
share repurchas
share repurchas
ep opm expans
price target impli ev ebitda
strong uptak new product launch
share repurchas
price multipl ev
stepped-up invest restor top-lin growth
heighten competit pressur lc mass spec
price multipl ev
wat core focu three analyt technolog
concentr asset util disciplin
capit redeploy philosophi contribut
above-averag profit industry-lead
cautiou wat exposur
pharmaceut end-market rev
deceler year sinc
upsid case lean heavili success
upcom new product cycl soon call/
quantifi abat china/eu headwind
pleas see import disclosur inform page report
water corporationhistor project valuat summarydollar million except per share amount fiscal year end decemb histor earn per flow cash cash flow cash flow per cash net interest free cash stock-bas sheet metricsreceiv day day day convers interest debt ttm debt ttm valu per water corpor jefferi llc estim equiti research
pleas see import disclosur inform page report
